ReShape Lifesciences Inc.

NasdaqCM:RSLS Stock Report

Market Cap: US$4.5m

ReShape Lifesciences Past Earnings Performance

Past criteria checks 0/6

ReShape Lifesciences has been growing earnings at an average annual rate of 9.2%, while the Medical Equipment industry saw earnings growing at 8.7% annually. Revenues have been declining at an average rate of 0.8% per year.

Key information

9.2%

Earnings growth rate

78.4%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate-0.8%
Return on equity-240.8%
Net Margin-131.0%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

Apr 18
It's A Story Of Risk Vs Reward With ReShape Lifesciences Inc. (NASDAQ:RSLS)

ReShape wins FDA clearance for device used in weight loss surgery

Aug 10

Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Mar 31
Analysts Have Lowered Expectations For ReShape Lifesciences Inc. (NASDAQ:RSLS) After Its Latest Results

Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Dec 09
Health Check: How Prudently Does ReShape Lifesciences (NASDAQ:RSLS) Use Debt?

Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Aug 24
Does ReShape Lifesciences (NASDAQ:RSLS) Have A Healthy Balance Sheet?

Revenue & Expenses Breakdown

How ReShape Lifesciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:RSLS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 248-11142
31 Dec 239-11182
30 Sep 2310-26212
30 Jun 2310-35262
31 Mar 2311-41292
31 Dec 2211-46313
30 Sep 2211-66332
30 Jun 2212-72403
31 Mar 2213-66363
31 Dec 2114-63312
30 Sep 2114-35273
30 Jun 2114-22152
31 Mar 2112-22153
31 Dec 2011-22153
30 Sep 2012-38163
30 Jun 2012-62183
31 Mar 2015-74213
31 Dec 1915-74223
30 Sep 1911-52223
30 Jun 198-28213
31 Mar 194-35184
31 Dec 181-38196
30 Sep 180-42227
30 Jun 181-47228
31 Mar 181-30237
31 Dec 171-30235
30 Sep 171-29195
30 Jun 171-25185
31 Mar 171-23185
31 Dec 161-23185
30 Sep 161-26216
30 Jun 161-23226
31 Mar 160-26217
31 Dec 150-25208
30 Sep 150-25179
30 Jun 150-261610
31 Mar 150-271511
31 Dec 140-261511
30 Sep 140-271511
30 Jun 140-271511
31 Mar 140-261411
31 Dec 130-261411
30 Sep 130-261411

Quality Earnings: RSLS is currently unprofitable.

Growing Profit Margin: RSLS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RSLS is unprofitable, but has reduced losses over the past 5 years at a rate of 9.2% per year.

Accelerating Growth: Unable to compare RSLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RSLS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.3%).


Return on Equity

High ROE: RSLS has a negative Return on Equity (-240.8%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.